TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7594142

Group type: EXPERIMENTAL
Intervention: Predictive equations for BMR: BMR = 13.88 x weight (kg) + 4.16 x height (cm) - 3.43 x age (years) - 112.40 x sex (men = 0; women = 1) + 54.34
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Indirect calorimetry measurement of BMR
Number of subjects: 223
Study: 1979946

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 26
Study: 6160639

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg per day for one week
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 31151855

Group type: EXPERIMENTAL
Intervention: Safety monitoring brochure/infographic
Number of subjects: 150

Group type: COMPARATOR
Intervention: Unrelated brochure
Number of subjects: 150
Study: 30567527

Group type: EXPERIMENTAL
Intervention: FOLFOX-4 chemotherapy (oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, 5-fluorouracil bolus 400 mg/m2 + infusion 600 mg/m2 for 2 days every 3 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Topotecan (1.5 mg/m2 every three weeks)
Number of subjects: 29
Study: 26016510

Group type: EXPERIMENTAL
Intervention: Gold Weight (GW)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Autogenous Temporalis Fascia (TF)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Contralateral eyelid (control)
Number of subjects: 18
Study: 24803301

Group type: EXPERIMENTAL
Intervention: Parent-led intervention (fathers taught their families about farm safety)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Staff-led intervention (staff members who were peer farmers taught families)
Number of subjects: 151

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Parent-led and staff-led interventions
Number of subjects: 151
Study: 21643644

Group type: EXPERIMENTAL
Intervention: Intradetrusor botulinum toxin-A (BTX-A)
Number of subjects: 32
Study: 20450723

Group type: EXPERIMENTAL
Intervention: Programmed hyperuricemic intervention
Number of subjects: 531
Study: 18619971

Group type: EXPERIMENTAL
Intervention: Vaccine consisting of recombinant VacA, CagA, and NAP with aluminium hydroxide as an adjuvant
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vaccine consisting of recombinant VacA, CagA, and NAP
Number of subjects: 57

Group type: COMPARATOR
Intervention: Alum controls
Number of subjects: 57
Study: 15747271

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 33

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 33
Study: 14671161

Group type: EXPERIMENTAL
Intervention: rhGH treatment (6 microg/kg.d)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 10964832

Group type: EXPERIMENTAL
Intervention: Scanning laser entoptic perimetry
Number of subjects: 23

Group type: COMPARATOR
Intervention: Achromatic threshold perimetry
Number of subjects: 23
Study: 8997054

Group type: EXPERIMENTAL
Intervention: Continuous epidural administration of fentanyl 33 micrograms/ml with 0.17% bupivacaine
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Continuous epidural administration of morphine 0.21 mg/ml with 0.17% bupivacaine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bolus epidural administration of fentanyl 100 micrograms
Number of subjects: 18

Group type: COMPARATOR
Intervention: Bolus epidural administration of morphine 3 mg
Number of subjects: 18
Study: 1430977

Group type: EXPERIMENTAL
Intervention: Buffered lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unbuffered lidocaine
Number of subjects: 0
Study: 2581855

Group type: EXPERIMENTAL
Intervention: Prednimustine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combination chemotherapy (cyclophosphamide, vincristine and prednisone)
Number of subjects: 24
Study: 30476976

Group type: EXPERIMENTAL
Intervention: Dapsone therapy for CSU
Number of subjects: 79
Study: 28391886

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks (Q2W)
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg every 2 weeks (Q2W)
Number of subjects: 1257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Alirocumab (both dosages)
Number of subjects: 1257
Study: 26883341

Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard supervised group-setting program
Number of subjects: 12
Study: 25147733

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - ten weekly intervention sessions
Number of subjects: 98

Group type: COMPARATOR
Intervention: Usual care (control group) - nutritional support and education
Number of subjects: 98
Study: 23065443

Group type: EXPERIMENTAL
Intervention: EUROACTION intervention programme
Number of subjects: 2024

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 2024
Study: 19160366

Group type: EXPERIMENTAL
Intervention: Modified Seldinger technique
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard open insertion
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard open insertion (as a rescue strategy)
Number of subjects: 164
Study: 17208600

Group type: EXPERIMENTAL
Intervention: Lactobacillus acidophilus (LAVRI‐A1)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study: 15827399

Group type: EXPERIMENTAL
Intervention: Tc-99m sulfur colloid
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Tc-99m MIBI
Number of subjects: 72
Study: 11990923

Group type: EXPERIMENTAL
Intervention: Noninvasive pressure support ventilation (NPSV) using a helmet
Number of subjects: 33

Group type: COMPARATOR
Intervention: Noninvasive pressure support ventilation (NPSV) using a facial mask
Number of subjects: 33
Study: 10860031

Group type: EXPERIMENTAL
Intervention: Composite graft (demineralized freeze-dried bone and doxycycline hyclate 4:1 by volume) with resorbable calcium sulfate barrier
Number of subjects: 7

Group type: COMPARATOR
Intervention: Surgical debridement only
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Composite graft with resorbable barrier
Number of subjects: 7
Study: 7782724

Group type: EXPERIMENTAL
Intervention: Fasting blood glucose (FBG) cut-off value of 6.7 mmol L-1
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Fasting blood glucose (FBG) cut-off value of 6.0 mmol L-1
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Fasting blood glucose (FBG) cut-off value of 4.8 mmol L-1
Number of subjects: 1843

Group type: EXPERIMENTAL
Intervention: Fasting blood glucose (FBG) optimal cut-off value of 5.3 mmol L-1
Number of subjects: 1843

Group type: COMPARATOR
Intervention: 2-h oral glucose tolerance test (OGTT)
Number of subjects: 1843
Study: 2371368

Group type: EXPERIMENTAL
Intervention: Haloperidol plasma level 2‐13 ng/ml
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Haloperidol plasma level 13.1‐24 ng/ml
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Haloperidol plasma level 24.1‐35 ng/ml
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Haloperidol (all levels)
Number of subjects: 111
Study: 27415

Group type: EXPERIMENTAL
Intervention: 0.1 N HCl infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.9% NaCl infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Various test solutions (distilled water, 0.9% NaCl, 1.8% NaCl, 3.6% NaCl, 0.1 N HCl, 0.2 N HCl)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.1 N HCl infusion with increased rate
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Bolus injection of intraluminal fluid
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cessation of bolus injection
Number of subjects: 9
Study: 30498908

Group type: EXPERIMENTAL
Intervention: Intradiscal delivery of mesenchymal stromal cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Growth factor-based therapies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Small molecule-based therapies
Number of subjects: 0
Study: 27548030

Group type: EXPERIMENTAL
Intervention: Modular treatment (MATCH)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Community-implemented treatment (CIT)
Number of subjects: 138
Study: 25433653

Group type: EXPERIMENTAL
Intervention: Sexual risk reduction intervention
Number of subjects: 1010

Group type: COMPARATOR
Intervention: General health promotion
Number of subjects: 1010

Group type: EXPERIMENTAL
Intervention: Sexual health assessment
Number of subjects: 1010

Group type: COMPARATOR
Intervention: General health assessment
Number of subjects: 1010
Study: 25112699

Group type: COMPARATOR
Intervention: IL9 gene expression in children with PA
Number of subjects: 30

Group type: COMPARATOR
Intervention: Machine-learning classification using IL9
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intracellular cytokine staining for IL-9 and IL-5
Number of subjects: 30
Study: 22229802

Group type: EXPERIMENTAL
Intervention: Group A (multi-ply cookware)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Group B (ordinary cookware)
Number of subjects: 3
Study: 19054570

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 18158692

Group type: EXPERIMENTAL
Intervention: 15-day pragmatic hamstring stretching program on one lower extremity
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control lower extremity (no stretching)
Number of subjects: 13
Study: 15349137

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (66 mg elemental iron)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Iron polymaltose complex (IPC) (100 mg elemental iron)
Number of subjects: 8

Group type: COMPARATOR
Intervention: No drug treatment (baseline)
Number of subjects: 8
Study: 11332584

Group type: EXPERIMENTAL
Intervention: 0.625mg/day of CEE orally
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1.25mg/day of CEE orally
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 50microg/day of transdermal 17beta‐estradiol
Number of subjects: 8

Group type: COMPARATOR
Intervention: No hormonal treatment
Number of subjects: 8
Study: 9434661

Group type: EXPERIMENTAL
Intervention: Zinc (25 mg as zinc sulfate)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Vitamin A (800 micrograms retinol palmitate)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Vitamin A and Zinc (800 micrograms retinol palmitate and 25 mg as zinc sulfate)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (starch capsules)
Number of subjects: 118
Study: 7859694

Group type: EXPERIMENTAL
Intervention: Sorbitol (2 x 15 g)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Maltitol (2 x 15 g)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isomalt (2 x 15 g)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sorbitol (5, 10, or 20 g)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Isomalt (5, 10, or 20 g)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Polyols (2 x 15 g intake)
Number of subjects: 11
Study: 2913680

Group type: EXPERIMENTAL
Intervention: Oxytocin induction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 vaginal tablets (0.5 mg) intravaginally every 6 hours
Number of subjects: 60

Group type: COMPARATOR
Intervention: Expectant management (bed rest and observation)
Number of subjects: 60
Study: 7402800

Group type: EXPERIMENTAL
Intervention: Iron-fortified formula
Number of subjects: 93

Group type: COMPARATOR
Intervention: Non-iron-fortified formula
Number of subjects: 93
Study: 30627829

Group type: EXPERIMENTAL
Intervention: Supportive underwear (shaper)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 89

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 89
Study: 28126022

Group type: EXPERIMENTAL
Intervention: Face-to-face intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Online intervention
Number of subjects: 100
Study: 25469821

Group type: EXPERIMENTAL
Intervention: Numeric Pain Rating Scale (NPRS) during physical testing
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Numeric Pain Rating Scale (NPRS)
Number of subjects: 18
Study: 23507071

Group type: EXPERIMENTAL
Intervention: Bipolar sealer (Aquamantys 6.0 bipolar sealer)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard monopolar electrocautery
Number of subjects: 200
Study: 21599551

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 41
Study: 19295201

Group type: EXPERIMENTAL
Intervention: Urokinase (UK) administered intraventricularly every 12 hours until clinical response permitted EVD removal
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (Pcb) administered intraventricularly every 12 hours until clinical response permitted EVD removal
Number of subjects: 11
Study: 17876342

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 101
Study: 15087045

Group type: EXPERIMENTAL
Intervention: 0.5 mg cabergoline
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1.0 mg cabergoline
Number of subjects: 80
Study: 11294800

Group type: EXPERIMENTAL
Intervention: Argatroban (2 microgram/kg/min IV, adjusted to maintain aPTT 1.5 to 3.0 times baseline)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control subjects (historical control)
Number of subjects: 304
Study: 9068520

Group type: EXPERIMENTAL
Intervention: Coronary sinus group (defibrillation electrodes in the right atrium and coronary sinus)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pulmonary artery group (defibrillation electrodes in the right atrium and left pulmonary artery)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 80
Study: 8422596

Group type: EXPERIMENTAL
Intervention: Stepwise disclosure of prognostic information by physicians
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapies
Number of subjects: 0
Study: 3758244

Group type: EXPERIMENTAL
Intervention: Dextromethorphan-salbutamol combination
Number of subjects: 108

Group type: COMPARATOR
Intervention: Dextromethorphan
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 12575602

Group type: EXPERIMENTAL
Intervention: Combination therapy (megestrol acetate and Chinese medicine)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Megestrol acetate alone
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 106
Study: 31405927

Group type: COMPARATOR
Intervention: 2 mg of the D2 antagonist haloperidol
Number of subjects: 53
Study: 28927869

Group type: EXPERIMENTAL
Intervention: initial combination therapy including prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: including infliximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: sequential DMARD monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: step-up combination therapy
Number of subjects: 0
Study: 28531893

Group type: EXPERIMENTAL
Intervention: HTR3A and HTR3B gene markers
Number of subjects: 149
Study: 25283471

Group type: EXPERIMENTAL
Intervention: Oral lenalidomide 10 mg once daily
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 22922604

Group type: EXPERIMENTAL
Intervention: Beverage containing soluble fiber, caffeine, and green tea catechins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beverage containing soluble fiber
Number of subjects: 0

Group type: COMPARATOR
Intervention: Equal calorie control beverage
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-beverage control condition
Number of subjects: 0
Study: 20108306

Group type: EXPERIMENTAL
Intervention: Group A (melanoma 1.0 mm to 1.59 mm)
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Group B (melanoma > or = 1.6 mm to 2.0 mm)
Number of subjects: 1110

Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 1110

Group type: COMPARATOR
Intervention: Group B
Number of subjects: 1110
Study: 17697248

Group type: EXPERIMENTAL
Intervention: Mtwo
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: K3
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: ProTaper
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: K3, Mtwo, ProTaper
Number of subjects: 210
Study: 15659723

Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg daily)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Aspirin plus esomeprazole (80 mg aspirin daily + 20 mg esomeprazole twice daily)
Number of subjects: 320
Study: 11856065

Group type: EXPERIMENTAL
Intervention: Paced gait at 120 steps/min
Number of subjects: 44

Group type: COMPARATOR
Intervention: Preferred gait speed
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Heel-strike measure
Number of subjects: 44
Study: 7485927

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 3 g/day for 5 days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 2181673

Group type: EXPERIMENTAL
Intervention: Salsalate
Number of subjects: 39

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 39
Study: 375435

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 31103018

Group type: EXPERIMENTAL
Intervention: Oxytocin (40 IU via nasal spray)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 28317674

Group type: EXPERIMENTAL
Intervention: Multifocal IOL
Number of subjects: 320

Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Both IOL types
Number of subjects: 320
Study: 25652239

Group type: EXPERIMENTAL
Intervention: Jean Rives (JR) technique
Number of subjects: 110

Group type: COMPARATOR
Intervention: Laparoscopic TEP repair
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Both groups (JR and TEP)
Number of subjects: 110
Study: 23937007

Group type: EXPERIMENTAL
Intervention: Hearing aids combined with psychological counseling therapy
Number of subjects: 154

Group type: COMPARATOR
Intervention: Counseling therapy only
Number of subjects: 154
Study: 21251382

Group type: EXPERIMENTAL
Intervention: tolterodine
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: oxybutynin
Number of subjects: 204

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 204
Study: 18664310

Group type: EXPERIMENTAL
Intervention: Free fruit provision
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Control (no free fruit)
Number of subjects: 2032
Study: 17537082

Group type: EXPERIMENTAL
Intervention: Green House (GH) model
Number of subjects: 120
Study: 15167120

Group type: EXPERIMENTAL
Intervention: 131I thyroid doses
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Short-lived radioiodines (132I, 133I, 135I) and radiotelluriums (131mTe, 132Te)
Number of subjects: 321
Study: 11848001

Group type: EXPERIMENTAL
Intervention: Magnesium citrate orally the evening before, clear liquid diet and two Fleet enemas 1 hour before the procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnesium citrate orally the evening before, clear liquid the day of the exam, and two Dulcolax suppositories the day of the exam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two Fleet enemas
Number of subjects: 0
Study: 9204088

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel + Benzoyl peroxide
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel + Clindamycin phosphate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% gel + Erythromycin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Benzoyl peroxide alone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Clindamycin phosphate alone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Erythromycin alone
Number of subjects: 25
Study: 8435259

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.5 mg kg‐1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pancuronium 70 micrograms kg‐1
Number of subjects: 40

Group type: COMPARATOR
Intervention: Tubocurarine 0.5 mg kg‐1
Number of subjects: 40
Study: 3657041

Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Untreated essential hypertension
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mechanical stress on RBCs
Number of subjects: 50
Study: 31362007

Group type: EXPERIMENTAL
Intervention: Clip closure of mucosal defects using 11-mm through-the-scope clips (n=119)
Number of subjects: 235

Group type: COMPARATOR
Intervention: No clip closure (control group, n=116)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Clip closure of mucosal defects using 11-mm through-the-scope clips (n=119) after complete closure
Number of subjects: 235
Study: 28734853

Group type: EXPERIMENTAL
Intervention: D25 (dexmedetomidine 25 μg kg−1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: D25M300 (dexmedetomidine 25 μg kg−1 + MK-467 300 μg kg−1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: D25M600 (dexmedetomidine 25 μg kg−1 + MK-467 600 μg kg−1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: D25M1200 (dexmedetomidine 25 μg kg−1 + MK-467 1200 μg kg−1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: M600 (MK-467 600 μg kg−1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: All treatments with dexmedetomidine
Number of subjects: 8
Study: 25912372

Group type: EXPERIMENTAL
Intervention: Educational interventions to increase HPV vaccination coverage
Number of subjects: 0
Study: 23909490

Group type: EXPERIMENTAL
Intervention: ERCC1 rs11615 A/A genotype
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: XPF rs6498486 C/C genotype
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Both ERCC1 rs11615 A allele and XPF rs6498486 C allele
Number of subjects: 384
Study: 21339423

Group type: EXPERIMENTAL
Intervention: Gastric bypass with duodenum exclusion (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sleeve gastrectomy without duodenum exclusion (n = 30)
Number of subjects: 60
Study: 19506498

Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (2 microg/kg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral midazolam (0.5 mg/kg)
Number of subjects: 100
Study: 16484572

Group type: EXPERIMENTAL
Intervention: Aged garlic extract (AGE) administered for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo administered for 6 months
Number of subjects: 50
Study: 15172399

Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 3541

Group type: COMPARATOR
Intervention: Balloon Angioplasty
Number of subjects: 3541